Key Drivers
- Huge cash reserves
- Zero revenue
- High cash burn
AIAI Summary
RVMD has shifted from speculative discovery risk to an event‑driven, late‑stage oncology investment whose valuation hinges on 2026 pivotal readouts and regulatory milestones—if Phase III/BTD pathways validate RAS(ON) efficacy the stock could reprice materially, but failures would likely trigger sharp dilution and valuation compression. Actionable plan: treat RVMD as a timing‑sensitive trade—size positions for binary outcomes, monitor cash runway vs. FY2026 burn and upcoming readout timelines closely, and set predefined stop‑loss or hedges ahead of key 2026 catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Huge cash reserves
- •Zero revenue
- •High cash burn
RVMD has a strong liquidity and low-leverage balance sheet but zero revenue, massive operating losses and cash burn funded by financing, while its market valuation appears highly stretched versus fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Near-term support
- •Resistance cluster
Over last month RVMD has trended down ~6% to $95.78, testing support near $94.86 while a break below risks the low-$80s and strength above ~$99–$101 would be a constructive sign.
Sharp spike to ~$123 then plunge to high-$70s in
Sentiment & News
Key News Insights:
- •Raised expense guidance
- •Late‑stage RAS focus
- •Institutional buy/sell mix
Revolution Medicines reported wider-than-expected Q4 losses and raised 2026 operating expense guidance to $1.6–$1.7B while pushing late‑stage RAS programs amid rising institutional buying but concurrent insider selling.
Advances in the RAS pipeline support long‑term value, but elevated 2026 spending and insider sales could weigh on near‑term share performance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings